Shanghai Junshi Biosciences Co Ltd (688180) - Total Liabilities
Based on the latest financial reports, Shanghai Junshi Biosciences Co Ltd (688180) has total liabilities worth CN¥6.16 Billion CNY (≈ $901.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Junshi Biosciences Co Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Shanghai Junshi Biosciences Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Shanghai Junshi Biosciences Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Shanghai Junshi Biosciences Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Junshi Biosciences Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avista Corporation
NYSE:AVA
|
USA | $5.63 Billion |
|
Xiangcai Co Ltd
SHG:600095
|
China | CN¥37.26 Billion |
|
SunocoCorp LLC
NYSE:SUNC
|
USA | $21.95 Billion |
|
Golub Capital BDC Inc
NASDAQ:GBDC
|
USA | $5.00 Billion |
|
Avient Corp
NYSE:AVNT
|
USA | $3.53 Billion |
|
Jiangsu Yangnong Chemical Co Ltd
SHG:600486
|
China | CN¥7.24 Billion |
|
Sino-American Silicon Products
TWO:5483
|
Taiwan | NT$150.14 Billion |
|
Knowles Cor
NYSE:KN
|
USA | $273.70 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Shanghai Junshi Biosciences Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Junshi Biosciences Co Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Junshi Biosciences Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Junshi Biosciences Co Ltd (2014–2025)
The table below shows the annual total liabilities of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.16 Billion ≈ $901.19 Million |
+26.99% |
| 2024-12-31 | CN¥4.85 Billion ≈ $709.68 Million |
+20.57% |
| 2023-12-31 | CN¥4.02 Billion ≈ $588.58 Million |
+44.58% |
| 2022-12-31 | CN¥2.78 Billion ≈ $407.10 Million |
+2.34% |
| 2021-12-31 | CN¥2.72 Billion ≈ $397.81 Million |
+25.30% |
| 2020-12-31 | CN¥2.17 Billion ≈ $317.48 Million |
+51.31% |
| 2019-12-31 | CN¥1.43 Billion ≈ $209.83 Million |
+53.17% |
| 2018-12-31 | CN¥936.18 Million ≈ $136.99 Million |
+832.68% |
| 2017-12-31 | CN¥100.38 Million ≈ $14.69 Million |
+347.80% |
| 2016-12-31 | CN¥22.41 Million ≈ $3.28 Million |
+58.27% |
| 2015-12-31 | CN¥14.16 Million ≈ $2.07 Million |
+8.34% |
| 2014-12-31 | CN¥13.07 Million ≈ $1.91 Million |
-- |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more